These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30358019)

  • 41. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advagraf(®) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts.
    Caillard S; Moulin B; Buron F; Mariat C; Audard V; Grimbert P; Marquet P
    Transpl Int; 2016 Aug; 29(8):860-9. PubMed ID: 26373896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed.
    Robertsen I; Åsberg A; Ingerø AO; Vethe NT; Bremer S; Bergan S; Midtvedt K
    Transplantation; 2015 Mar; 99(3):528-32. PubMed ID: 25148382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation.
    Méndez A; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Blanco A; Camós S; Pou L; Roman A
    Transplantation; 2014 Feb; 97(3):358-62. PubMed ID: 24492423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.
    Terrault NA; Tran TT; Schiff E; McGuire BM; Brown RS; Tupper R; Ramanathan S; Enejosa J; Zhong L; Zong J;
    Liver Int; 2009 Sep; 29(8):1178-83. PubMed ID: 19486291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients.
    Woillard JB; Debord J; Monchaud C; Saint-Marcoux F; Marquet P
    Clin Pharmacokinet; 2017 Dec; 56(12):1491-1498. PubMed ID: 28389935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Once-daily tacrolimus in living donor liver transplant recipients.
    Sugawara Y; Miyata Y; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
    Biosci Trends; 2011 Aug; 5(4):156-8. PubMed ID: 21914950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of prolonged-release versus immediate-release tacrolimus in
    Kim MS; Joh JW; Kim DS; Kim SH; Choi JS; Lee J; Lee JY; Kim JM; Kwon CHD; Choi GS; Yu YD; Yoon YI; Han JH; Lee YJ; Jiang H; Kim SI
    Korean J Transplant; 2019 Jun; 33(2):20-29. PubMed ID: 35769149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
    Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.
    Zhao W; Maisin A; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 May; 69(5):1181-5. PubMed ID: 23208323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients.
    Min SI; Ha J; Kim YS; Ahn SH; Park T; Park DD; Kim SM; Min SK; Hong H; Ahn C; Kim SJ
    Nephrol Dial Transplant; 2013 Dec; 28(12):3110-9. PubMed ID: 24084327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients.
    Takahashi Y; Shishido S; Hyodo Y; Yonekura T; Nihei H; Itabashi Y; Muramatsu M; Hamasaki Y; Kawamura T; Aikawa A
    Transplant Proc; 2017; 49(1):37-40. PubMed ID: 28104153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients.
    Naesens M; Salvatierra O; Li L; Kambham N; Concepcion W; Sarwal M
    Transplantation; 2008 Apr; 85(8):1139-45. PubMed ID: 18431234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
    Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
    Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Converting immunosuppression from an oral suspension to a granule formulation of tacrolimus in pediatric renal transplant recipients.
    Malakasioti G; Booth C; Marks SD
    Pediatr Transplant; 2018 Aug; 22(5):e13214. PubMed ID: 29767471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.